Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19477925 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Pedram A, et al. (2009) Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 20, 3374-89 19477925
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase

Y15-p - CDK1 (human)
Orthologous residues
CDK1 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
estrogen UV inhibit treatment-induced increase
estrogen no change compared to control
hydroxyurea increase
estrogen hydroxyurea inhibit treatment-induced increase

S280-p - Chk1 (human)
Orthologous residues
Chk1 (human): S280‑p, Chk1 (mouse): S280‑p, Chk1 (rat): S280‑p, Chk1 (chicken): S280‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase
LY294002 estrogen inhibit treatment-induced increase
estrogen Akt1 (human) inhibit treatment-induced increase DN Akt mutant
siRNA estrogen inhibit treatment-induced increase Akt siRNA
UV no change compared to control
hydroxyurea no change compared to control

S345-p - Chk1 (human)
Orthologous residues
Chk1 (human): S345‑p, Chk1 (mouse): S345‑p, Chk1 (rat): S345‑p, Chk1 (chicken): S345‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1569 (breast cell), MCF-7 (breast cell), T47D (breast cell), ZR-75-1 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ATR (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
estrogen ionizing radiation inhibit treatment-induced increase
PPT ionizing radiation inhibit treatment-induced increase
DPN ionizing radiation no effect upon treatment-induced increase
estrogen, AG1478 ionizing radiation no effect upon treatment-induced increase
AG1478 ionizing radiation no effect upon treatment-induced increase
EGF ionizing radiation inhibit treatment-induced increase
LY294002, EGF ionizing radiation no effect upon treatment-induced increase
hydroxyurea increase
estrogen hydroxyurea inhibit treatment-induced increase
estrogen, ICI 182,780 hydroxyurea no effect upon treatment-induced increase
PPT hydroxyurea inhibit treatment-induced increase
DPN hydroxyurea no effect upon treatment-induced increase
ICI 182,780 no change compared to control
estrogen no change compared to control
LY294002 no change compared to control
ionizing radiation EGFR (human) no effect upon treatment-induced increase DN EGFR mutant
UV increase
estrogen UV inhibit treatment-induced increase
UV ER-alpha (human) no effect upon treatment-induced increase S522A ER-alpha mutant
progesterone UV no effect upon treatment-induced increase
testosterone UV no effect upon treatment-induced increase
LY294002, estrogen UV no effect upon treatment-induced increase
estrogen, AG1478 UV no effect upon treatment-induced increase
AG1478 UV no effect upon treatment-induced increase
EGF UV inhibit treatment-induced increase
LY294002, EGF UV no effect upon treatment-induced increase
LY294002 no change compared to control
UV EGFR (human) no effect upon treatment-induced increase DN EGFR mutant
estrogen UV EGFR (human) no effect upon treatment-induced increase DN EGFR mutant
estrogen UV Akt1 (human) no effect upon treatment-induced increase
siRNA, estrogen UV no effect upon treatment-induced increase Akt siRNA
hydroxyurea increase
LY294002, estrogen hydroxyurea no effect upon treatment-induced increase
estrogen hydroxyurea Akt1 (human) no effect upon treatment-induced increase DN Akt mutant
siRNA, estrogen hydroxyurea no effect upon treatment-induced increase Akt siRNA
siRNA, estrogen hydroxyurea inhibit treatment-induced increase
ER-alpha (human) no change compared to control
UV ER-alpha (human) increase
estrogen UV ER-alpha (human) inhibit treatment-induced increase
estrogen ER-alpha (human) no change compared to control

S15-p - p53 (human)
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ATR (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
estrogen ionizing radiation inhibit treatment-induced increase
PPT ionizing radiation inhibit treatment-induced increase
DPN ionizing radiation no effect upon treatment-induced increase
estrogen, AG1478 ionizing radiation no effect upon treatment-induced increase
AG1478 ionizing radiation no effect upon treatment-induced increase
EGF ionizing radiation inhibit treatment-induced increase
LY294002, EGF ionizing radiation no effect upon treatment-induced increase
hydroxyurea increase
estrogen hydroxyurea inhibit treatment-induced increase
estrogen, ICI 182,780 hydroxyurea no effect upon treatment-induced increase
PPT hydroxyurea inhibit treatment-induced increase
DPN hydroxyurea no effect upon treatment-induced increase
ICI 182,780 no change compared to control
estrogen no change compared to control
LY294002 no change compared to control
ionizing radiation EGFR (human) no effect upon treatment-induced increase DN EGFR mutant
UV increase
estrogen UV inhibit treatment-induced increase
estrogen, AG1478 UV no effect upon treatment-induced increase
AG1478 UV no effect upon treatment-induced increase
EGF UV inhibit treatment-induced increase
LY294002, EGF UV no effect upon treatment-induced increase
UV EGFR (human) no effect upon treatment-induced increase DN EGFR mutant
LY294002 no change compared to control

S1159-p - TOPBP1 (human)
Orthologous residues
TOPBP1 (human): S1159‑p, TOPBP1 (mouse): S1161‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
estrogen increase
UV estrogen no change compared to control
LY294002 estrogen inhibit treatment-induced increase
UV no change compared to control
LY294002 no change compared to control
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ATR (human) Disrupts co-immunoprecipitation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.